TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
The latest update is out from COSCIENS Biopharma ( (TSE:CSCI) ).
COSCIENS Biopharma Inc. reported a 35.2% increase in revenues for 2024, reaching $9.6 million, and ended the year with $16.4 million in cash. The company has stopped investing in certain pre-clinical programs following negative trial results and is focusing on natural-based products to drive future growth. Key developments include successful Phase 1 results for Avenanthramides Tablets, the launch of a new cosmeceutical website, and plans to commercialize new nutraceutical products in 2025. The company is also advancing its PGX technology for scalable production of biopolymers.
More about COSCIENS Biopharma
COSCIENS Biopharma Inc. is a life science company that develops and commercializes a diverse portfolio of cosmeceutical, nutraceutical, and pharmaceutical products. The company is focused on natural-based products and has recently undergone a strategic repositioning to streamline operations and prioritize its product pipeline.
YTD Price Performance: -10.26%
Average Trading Volume: 24,335
Technical Sentiment Signal: Strong Buy
Current Market Cap: $7.77M
Learn more about CSCI stock on TipRanks’ Stock Analysis page.